We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Soft tissue sarcoma

News List

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 americanpharmaceuticalreview
November 11, 2020
Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613® (devimistat) for the treatment of soft tissue sarcoma.
Cancer drug with accelerated approval fails Phase III trial europeanpharmaceuticalreview
January 24, 2019
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma americanpharmaceuticalreview
June 22, 2017
Epizyme announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to tazemetostat, the company’s first-in-class EZH2 inhibitor, for the treatment of patients with soft tissue sarcoma (STS).